Form 4: Enanta Pharmaceuticals Executive Tara Lynn Kieffer Reports Stock Transactions

Tara Lynn Kieffer, Chief Product Strategy Officer at Enanta Pharmaceuticals, reports acquisition of 7,500 shares and disposal of 3,326 shares to cover withholding taxes.

Summary

• On February 12, 2025, Tara Lynn Kieffer, Chief Product Strategy Officer of Enanta Pharmaceuticals, acquired 7,500 shares of common stock.
• These shares were issued under performance share units (PSUs) that vested based on the achievement of two-year research and development milestones in the 2023-2024 period.
• The vesting was determined by the Compensation Committee of Enanta's Board of Directors.
• Also on February 12, 2025, Ms. Kieffer disposed of 3,326 shares of common stock at a price of $5.59.
• This disposal was to cover withholding taxes due as a result of the settlement of the PSU awards.
• Following these transactions, Ms. Kieffer beneficially owns 33,479 shares of Enanta Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing represents standard stock transactions related to executive compensation. There is no indication of positive or negative news regarding the company's performance.

Positives

• The vesting of performance share units indicates that research and development milestones were achieved during the 2023-2024 period.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry as part of executive compensation packages.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates

Keywords

Enanta Pharmaceuticals, Tara Lynn Kieffer, Form 4, Stock Transaction, Performance Share Units, PSU, Beneficial Ownership, ENTA